Core Viewpoint - Baxter International Inc. is set to announce its second-quarter 2025 results on July 31, with expectations of moderate growth despite a projected decline in revenues and earnings compared to the previous year [1][2][3]. Q2 Estimates - The consensus estimate for revenues is $2.82 billion, reflecting a 26.1% decline from the prior year's quarter [2]. - The consensus estimate for earnings is 60 cents per share, indicating an 11.8% year-over-year decline [2]. - The model estimates total revenues from continuing operations to improve by 1.3% at constant currency to $2.81 billion, with adjusted earnings per share expected to decline 11.4% to 60 cents [2]. Important Factors to Note - Baxter is anticipated to report moderate growth supported by strong execution across core segments and easing operational challenges [3]. - Sales from continuing operations grew 5% in the first quarter, driven by the Medical Products & Therapies and Healthcare Systems & Technologies segments [3]. - For Q2, the company expects reported sales growth of approximately 4% to 5% and operational growth in the 1% to 2% range [3]. Margin Profile - Baxter's adjusted operating margin improved by 260 basis points year-over-year to 14.9%, aided by strong top-line delivery and lower SG&A expenses [4]. - The margin stability is expected to continue due to operational efficiencies and ongoing cost containment initiatives [4]. Operational Performance - The completion of Baxter's transformation strategy, including the spin-offs of the Kidney Care and BioPharma Solutions businesses, has streamlined its portfolio [5]. - Management expects adjusted earnings per share in the range of 59 to 63 cents, building on the 55 cents reported in the previous quarter [5]. Recovery from Hurricane Helene - Manufacturing at the North Cove facility has returned to pre-hurricane levels, allowing for inventory replenishment and reduced product allocations [6]. - The company anticipates normalized ordering patterns as IV solution product allocations are removed [6]. Segmental Overview - The Medical Products & Therapies segment reported a 6% operational growth in Q1, with sales reaching $1.3 billion, driven by the U.S. infusion systems portfolio [7][9]. - The Healthcare Systems & Technologies segment also saw a 6% operational increase in Q1, with sales totaling $704 million, led by the Care and Connectivity Solutions division [10]. - The Pharmaceuticals segment reported 3% operational growth in Q1, with sales of $581 million, primarily driven by specialty injectables [11]. Other Sales and Revenue Streams - Other sales totaled $15 million in Q1, with drug compounding business growing 2% [12]. - MSA revenue from Vantive was reported at $63 million in Q1, with expectations of around $80 million for Q2 [12].

Financial Data and Key Metrics Changes - First quarter sales from continuing operations grew 5% on both a reported and operational basis, totaling $2.63 billion, exceeding previous guidance of 3% to 4% [8][13][34] - Adjusted earnings per share from continuing operations were $0.55, up 53% compared to the prior year, driven by favorable top line results and lower non-operational expenses [8][33] Business Line Data and Key Metrics Changes - Medical Products and Therapies (MPT) segment sales were $1.3 billion, increasing 6%, with strong growth in U.S. infusion systems [14][35] - Healthcare Systems and Technologies (HST) segment sales totaled $704 million, up 6%, driven by 14% growth in the U.S. for Care and Connectivity Solutions [19][20] - Pharmaceutical segment sales were $581 million, increasing 3%, with specialty injectables showing mid-single-digit growth [23] Market Data and Key Metrics Changes - The U.S. market showed strong recovery with hospitals beginning to rebuild inventory levels, particularly in IV Solutions, which is expected to improve as allocations are removed [17][22] - International sales performance was weaker, but capital orders picked up, indicating potential future growth [20] Company Strategy and Development Direction - The company is focused on leveraging its verticalized operating model to enhance innovation and drive profitable growth [6][8] - Strategic actions are being taken to mitigate the impact of global tariffs and optimize the supply chain [9][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic trajectory despite global macroeconomic volatility and uncertainty [9][10] - The company anticipates total sales growth of 7% to 8% for the full year 2025, with operational growth expected at 4% to 5% [34][42] Other Important Information - The search for a permanent CEO is active, with the board working with a leading search firm [10] - The company is committed to accelerating investments in innovation to redefine healthcare delivery [27] Q&A Session Summary Question: What actions are being taken to offset tariff headwinds? - Management is optimizing supply chains, negotiating with suppliers, and seeking exemptions while implementing targeted pricing strategies [46][50] Question: What is the outlook for the HST business recovery? - The HST segment showed strong performance with a healthy backlog and competitive wins, indicating positive momentum [52][54] Question: What impact do conservation programs have on IV Solutions? - Hospitals are expected to continue conservation efforts, but some are using more solutions than pre-hurricane levels, indicating a mixed recovery [60][62] Question: How is the company addressing potential pharmaceutical tariffs? - The company is proactively planning for potential tariff impacts and seeking exemptions, but the situation remains uncertain [66][68] Question: What is the outlook for operating margins in 2026? - The company remains committed to margin expansion, but the impact of tariffs and other factors will be evaluated as the situation develops [100]

Financial Data and Key Metrics Changes - First quarter sales from continuing operations grew 5% on both a reported and operational basis, totaling $2.63 billion, exceeding previous guidance of 3% to 4% [6][12] - Adjusted earnings per share from continuing operations were $0.55, up 53% compared to the prior year, driven by favorable top line results and lower non-operational expenses [27][33] - Adjusted gross margin from continuing operations was 41.8%, a decrease of 160 basis points year-over-year, impacted by higher planning and fulfillment costs [29] Business Line Data and Key Metrics Changes - Medical Products and Therapies (MPT) segment sales were $1.3 billion, increasing 6%, with strong growth in U.S. Infusion systems [13][14] - Healthcare Systems and Technologies (HST) segment sales totaled $704 million, increasing 6%, driven by 14% growth in the U.S. for Care and Connectivity Solutions [18][19] - Pharmaceutical segment sales were $581 million, increasing 3%, with injectables and anesthesia sales growing 4% [22] Market Data and Key Metrics Changes - The U.S. market showed strong recovery with hospitals beginning to rebuild inventory levels, particularly in IV Solutions, which is expected to improve as allocations are removed [16][62] - International procurement remains a part of operations, with ongoing impacts from U.S. and retaliatory tariffs affecting the supply chain [39][40] Company Strategy and Development Direction - The company is focused on leveraging its verticalized operating model to enhance agility and drive profitable growth [5] - Continued investments in innovation are prioritized to bring new products to market and redefine healthcare delivery [26] - The search for a permanent CEO is active, with the board working with a leading search firm to identify the right candidate [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the volatility in the global macro environment and the uncertainty created by new tariffs, but remains positive about opportunities for sales growth and margin expansion [8][34] - The company expects total sales growth of 7% to 8% on a reported basis for the full year 2025, with operational growth of 4% to 5% [35][42] Other Important Information - The company is actively working on mitigating the impacts of tariffs, including optimizing supply chains and seeking exemptions [40] - Adjusted operating margin from continuing operations is expected to be between 16% to 16.5% for the full year [41] Q&A Session Summary Question: What actions are being taken to offset tariff headwinds? - Management is optimizing supply chains, negotiating with suppliers, and seeking exemptions while maintaining targeted pricing strategies [47][48] Question: How should we think about the sustainability of the HST business recovery? - The HST segment has shown strong order growth and competitive wins, with management optimistic about its future performance despite monitoring the capital environment [52][56] Question: What is the expected impact of IV Solutions on the business as hospitals return to normal inventory levels? - Hospitals are expected to continue conservation efforts, but some are using more solutions than pre-hurricane levels, indicating a mixed recovery [60][62] Question: Can you provide clarity on the potential impact of pharmaceutical tariffs? - The company is monitoring the situation closely, with a small exposure from the Clarus plant, and is proactive in scenario planning [66] Question: What are the expectations for operating margin expansion in 2026? - Management remains committed to margin expansion, but acknowledges that the tariff environment will influence future projections [100][102]

Core Viewpoint - Baxter International Inc. is expected to report first-quarter 2025 results on May 1, with a consensus estimate for revenues at $2.57 billion, reflecting a 28.4% decline year-over-year, and earnings per share (EPS) estimated at 48 cents, indicating a 26.2% year-over-year decline [1][2]. Revenue Estimates - The consensus estimate for total revenues is $2.57 billion, which represents a significant decline of 28.4% from the prior-year quarter [1]. - The model estimates total revenues from continuing operations to improve by 3.8% at constant currency to $2.58 billion [2]. Growth Factors - Baxter is likely to report moderate growth due to strong momentum in certain product lines, aided by easing macroeconomic pressures, with sales from continuing operations improving by 2% at constant currency in Q4 2024 [3]. - The company anticipates sales growth from continuing operations to be in the range of 3-4% [3]. Margin and Cost Considerations - Margins declined in the last reported quarter primarily due to one-time costs, including goodwill impairment charges and business optimization costs, which are expected to be reduced in the first quarter, potentially boosting the bottom line [4]. - The completion of a transformational plan, including the spin-off of certain business segments, is expected to enhance operational efficiency and improve EPS to a range of 47-50 cents [5]. Impact of Hurricane Helene - Baxter's recovery from Hurricane Helene has ensured minimal disruption in 2025, with all manufacturing lines restored to pre-hurricane levels, securing supply continuity [6]. - The Medical Products & Therapies segment is expected to have recovered from the hurricane's impact, aiding sales during the first quarter [7]. Segment Performance - Strong growth in infusion therapies, particularly the Novum IQ pump platform, is expected to continue, contributing positively to sales [8]. - The growth of parenteral nutrition products and Advanced Surgery products, along with recovery in IV solutions sales, is anticipated to drive segmental sales up by 6.6% at constant currency to $1.28 billion [9]. - The Healthcare Systems & Technologies segment may face challenges due to softness in the U.S. primary care market and delays in international capital spending, but patient support systems are expected to show resilience [10]. - The Pharmaceuticals segment is likely to improve, driven by a rebound in injectable drug sales and strong demand in drug compounding, with estimated sales growth of 14.4% at constant currency to $280.4 million [12][13].